AIT effectiveness and quality of life in patients diagnosed with
COVID-19 infection during the study period
During the study period, 12 patients were diagnosed with COVID-19. The
mean age of the patients was 37.5±11.5 and 7 (58.3%) of them were
female. 11 (91.7%) patients had AR and 1 (8.3%) had concomitant
allergic asthma. In 9 patients (75%), AIT was for HDMs and in 3
patients (25%), it was for pollens.
9 out of the 12 patients missed SCIT administration due to having
COVID-19 infection whereas the remaining 3 patients had SCIT injections
on time after completing the quarantine period. While 11 patients had
mild symptoms, 1 patient had to stay in hospital due to severe COVID-19
disease.
TSS-6, VAS-symptom and MSs of the patients (n=3) who had administration
on time were similar during pre-pandemic and the pandemic periods. 2 out
of the 3 patients had similar VAS-QoL scores during the pre-pandemic and
the pandemic periods whereas the pre-pandemic VAS-QoL score was 10 and
pandemic score was 9 in the third patient. The TSS-6, VAS-symptom,
VAS-QoL and MS median (IQR 25-75) scores during the pre-pandemic period
in the patients (n=9) who missed administration were 3 (1-4), 3 (1-5.5),
8 (7.5-9), 0 (0-1), respectively and during the pandemic, they were 5
(2.5-14.5), 7 (3-9.5), 7 (2.5-7.5), 1 (0-2), respectively.